Protocol Ledger

NCT05943535 · Phase III · RECRUITING

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

Interventional Phase III clinical trial protocol NCT05943535 sponsored by United Therapeutics in Respiratory and Pulmonary, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-10-30 Enrollment: 698 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05943535
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)698 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05943535
Protocol FieldVerified Registry Value
NCT IdentifierNCT05943535
Consolidated Lead SponsorUnited Therapeutics
Therapeutic Condition CohortRespiratory and Pulmonary
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment698 participants (ESTIMATED)
Registered Start Date2023-10-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI